<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Before the $3.2 billion acquisition of mRNA player Translate Bio Inc (NASDAQ: TBIO) earlier this month, Sanofi SA (NASDAQ: SNY) expressed interest in selling off around 25% of its shares in the company, which it had been working with since 2018. Translate Bio filed SEC document to give an inside look at how the buyout negotiations played out.
...read full article on Benzinga
